Reply to survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status

Hwang, E. Shelley; Clarke, Christina A.; Gomez, Scarlett Lin

doi:10.1002/cncr.28181

Cited by 32 publications

(59 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our analysis showed a 42% improved DSS with BCT over mastectomy, and this is similar to findings from 2 other studies. 15, 16 Hwang et al 15 used the California Cancer Registry to study earlystage breast cancer and showed a 15% improvement in DSS for BCT versus mastectomy. Agarwal et al 16 used the SEER database and found a 31% improvement in DSS for BCT versus mastectomy.…”

Section: Discussionmentioning

confidence: 99%

Is mastectomy undertreatment for low‐risk breast cancers eligible for breast‐conserving therapy?

Bagaria

Wasif

Rawal

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND: Biomarkers are routinely used to predict responses to systemic therapies, but their utility for predicting responses to local therapy for breast cancer is not known. This study determined whether biomarkers could predict responses to breastconserving therapy (BCT) and mastectomy. METHODS: A review of the Surveillance, Epidemiology, and End Results database identified women diagnosed with early-stage invasive ductal breast cancer and treated with BCT or mastectomy from 1998 to 2008. The estrogen receptor (ER) status and the histologic grade were used to construct 3 biomarker profiles: low risk (ER-positive, low/intermediate grade), intermediate risk (ER-positive, high grade), and high risk (ER-negative, any grade). The primary measured outcome was disease-specific survival (DSS). RESULTS: BCT and mastectomy were performed in 114,486 patients (59.2%) and 79,035 patients (40.8%), respectively. There were 122,420 low-risk patients (63.3%), 34,341 intermediate-risk patients (17.7%), and 36,760 high-risk patients (19.0%). Multivariate analyses were performed separately for patients with low-, intermediate-, and high-risk tumors. The adjusted hazard ratios for DSS for patients who underwent mastectomy versus BCT for low-, intermediate-, and high-risk tumors were 1.66 (95% confidence interval [CI], 1.54-1.79; P <.001), 1.40 (95% CI, 1.29-1.53; P <.001), and 1.27 (95% CI, 1.19-1.35; P <.001), respectively. CONCLUSIONS: Patients with ER-positive, low-grade breast cancers who underwent mastectomy had a 66% increase in disease-specific mortality versus those who underwent BCT. Biomarker profiles defined by the ER status and grade may improve the selection of local therapy for breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Is mastectomy undertreatment for low‐risk breast cancers eligible for breast‐conserving therapy?

Bagaria

Wasif

Rawal

et al. 2015

Cancer

View full text Add to dashboard Cite

show abstract

“…Nylig publiserte resultater fra en multisenterstudie med 22 års oppføl-ging bestrider imidlertid dette -forfatterne konkluderer med at behandlingsregimer med brystbevarende kirurgi og mastektomi er sidestilt med henblikk på overlevelse og dødelighet (9). En stor registerstudie fra USA viser til og med at mastektomi gir lavere overlevelse enn brystbevarende kirurgi (10).…”

Section: Materiale Og Metodeunclassified

“…Funnene er i strid med resultater fra andre studier og er omdiskutert (6,7,9,(17)(18)(19). Nye studier viser at den tilsynelatende overdødeligheten etter brystbevarende kirurgi ikke er reell (9) og at mastektomi muligens har dårligst resultater (10).…”

Section: Lk-63unclassified

Brystkreftkirurgi i Norge 1986 – 2009

Hofvind¹,

Schlichting²,

Ursin³

et al. 2013

Tidsskriftet

View full text Add to dashboard Cite

“…1 This difference in income may partially explain the difference in the survival rate. Several studies 2,3 have demonstrated that higher income women consume more alcohol than lower income women, and it has been well established that alcohol consumption increases the risk of breast cancer.…”

mentioning

confidence: 99%

Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status

Glas

Kiderlen

Liefers

2013

Cancer

View full text Add to dashboard Cite

show abstract

Reply to survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status

Cited by 32 publications

References 4 publications

Is mastectomy undertreatment for low‐risk breast cancers eligible for breast‐conserving therapy?

Is mastectomy undertreatment for low‐risk breast cancers eligible for breast‐conserving therapy?

Brystkreftkirurgi i Norge 1986 – 2009

Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status

Contact Info

Product

Resources

About